Pfizer on schedule to consolidate Enbrel franchise as ozoralizumab hits RA endpoint
This article was originally published in Scrip
Pfizer's bid to maintain the franchise of its rheumatoid arthritis blockbuster Enbrel's took another step when Ablynx, Pfizer's Belgium-based licensor announced top-line results of Pfizer's phase II clinical trial of ozoralizumab in rheumatoid arthritis. If ozoralizumab (ATN-103), an anti-TNF-alpha nanobody, match Enbrel in the clinic, its cost-of-good advantage might not only help Pfizer fight its corner against other branded TNF-inhibitors, but also repel the onslaught of biosimilar manufacturers that will emerge as Enbrel starts to come of patent in 2012.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.